Monday Moves [10/22/12]

Executive moves and new appoints at TearScience, Vasular Pathways, and Thoratec. OMNIlife science announces changes to board and management team.

 

 
Wade Hampton Appointed Senior VP and CCO at TearScience
 
Medical device company TearScience has appointed Wade Hampton as senior vice president and chief commercial officer. Hampton will focus on the commercialization of TearScience’s dry eye treatment system, the Lipiflow, particularly in North America. Previously, Hampton was a managing partner of Baron Minor Group, an aesthetic, surgical and ophthalmic medical device company. His resume also includes stints at Accuray Inc. and Lumenis Inc. [Triangle Business Journal]
 
Vascular Pathways Names Gina Gilbert as VP of Clinical Affairs
 
Vascular Pathways, a private medical device company which is commercializing the AccuCath Intravenous Catheter System for IV insertion, has appointed Gina Gilbert as vice president of clinical affairs. Gilbert has over 15 years of experience in the medical device industry. Most recently she was the senior director, clinical training and education for Bard Medical, leading the clinical organization for Bard’s catheter stabilization, urological, and fecal incontinence product lines. Vascular Pathways recently completed a $13.5 million financing from leading venture capital firms CHL Medical Partners, Ascension Health Ventures, MVM Life Sciences, and Arcus Ventures. [PR Web]
 
 
Thoratec Appoints Taylor C. Harris as Chief Financial Officer
 
Thoratec, a manufacturer of mechanical circulatory support products for patients suffering from advanced heart failure, has appointed Taylor C. Harris as Vice President and Chief Financial Officer. Harris joined Thoratec in 2010 as senior director of investor relations and business development.  Prior to joining Thoratec, he worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a VP in the firm's healthcare investment banking and equity research departments. In these roles, Mr. Harris covered the medical device sector as an investment research analyst and advised healthcare companies on a broad range of strategic and capital markets transactions. [PR Newswire]

Changes to Board of Directors and Management Team at OMNIlife science

OMNIlife science Inc., a subsidiary of Orthopaedic Synergy Inc. (OSI), and a manufacturers of orthopedic medical devices has announced the following changes to its board of directors and management team: Richard “Nik” Nikolaev has announced his retirement as a member of the board of directors after six years as a board member. Dr. Florian Reinaud, a partner at Paris-based Innovation Capital and a former Praxim board member, recently joined the OSI board of directors. Thomas Prokop, VP of sales has also announced his retirement after being with the company since 2007. Jack Turner will join the executive team as VP of sales. Before joining OMNIlife science, Turner was the national director of sales for Mako Surgical, where he identified strategic and tactical opportunities for improvement that resulted in significant revenue increases over a two-year period. Finally, Albert “Skip” Farinha has also joined the management team as VP of quality assurance. Farinha comes to OMNIlife science with over 25 years of quality and regulatory experience. Farinha will provide leadership for the development, implementation, communication, and maintenance of quality systems policies and procedures for OMNI in accordance with domestic and international regulations and ISO requirements. [PR Web
 

 

 

No votes yet